IL251027A0 - History of pyrrolopyrimidines as nr2b nmda receptor antagonists - Google Patents
History of pyrrolopyrimidines as nr2b nmda receptor antagonistsInfo
- Publication number
- IL251027A0 IL251027A0 IL251027A IL25102717A IL251027A0 IL 251027 A0 IL251027 A0 IL 251027A0 IL 251027 A IL251027 A IL 251027A IL 25102717 A IL25102717 A IL 25102717A IL 251027 A0 IL251027 A0 IL 251027A0
- Authority
- IL
- Israel
- Prior art keywords
- receptor antagonists
- nmda receptor
- pyrrolopyrimidine derivatives
- nr2b nmda
- nr2b
- Prior art date
Links
- 229940127523 NMDA Receptor Antagonists Drugs 0.000 title 1
- 108010054200 NR2B NMDA receptor Proteins 0.000 title 1
- 150000004944 pyrrolopyrimidines Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462050692P | 2014-09-15 | 2014-09-15 | |
| PCT/US2015/050267 WO2016044323A1 (en) | 2014-09-15 | 2015-09-15 | Pyrrolopyrimidine derivatives as nr2b nmda receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL251027A0 true IL251027A0 (en) | 2017-04-30 |
Family
ID=54293326
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL251027A IL251027A0 (en) | 2014-09-15 | 2017-03-08 | History of pyrrolopyrimidines as nr2b nmda receptor antagonists |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US9567341B2 (enExample) |
| EP (1) | EP3194403B1 (enExample) |
| JP (1) | JP6612331B2 (enExample) |
| KR (1) | KR102569031B1 (enExample) |
| CN (1) | CN106715435B (enExample) |
| AU (1) | AU2015317886A1 (enExample) |
| CA (1) | CA2957898C (enExample) |
| DK (1) | DK3194403T3 (enExample) |
| ES (1) | ES2723436T3 (enExample) |
| IL (1) | IL251027A0 (enExample) |
| MX (1) | MX2017002775A (enExample) |
| RU (1) | RU2017107558A (enExample) |
| SG (1) | SG11201701853YA (enExample) |
| WO (1) | WO2016044323A1 (enExample) |
| ZA (1) | ZA201701069B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3152213B1 (en) * | 2014-06-04 | 2018-10-31 | Rugen Holdings (Cayman) Limited | Difluoroethylpyridine derivatives as nr2b nmda receptor antagonists |
| DK3194403T3 (en) | 2014-09-15 | 2019-04-15 | Rugen Holdings Cayman Ltd | PYRROLOPYRIMIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS |
| US10221182B2 (en) | 2015-02-04 | 2019-03-05 | Rugen Holdings (Cayman) Limited | 3,3-difluoro-piperidine derivatives as NR2B NMDA receptor antagonists |
| WO2016196513A1 (en) | 2015-06-01 | 2016-12-08 | Rugen Holdings (Cayman) Limited | 3,3-difluoropiperidine carbamate heterocyclic compounds as nr2b nmda receptor antagonists |
| US10487055B2 (en) | 2016-06-01 | 2019-11-26 | Rhode Island Board Of Education | Diindole compounds useful in treatment of nervous system disorders |
| US11000526B2 (en) | 2016-11-22 | 2021-05-11 | Rugen Holdings (Cayman) Limited | Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders |
| IL274868B2 (en) * | 2017-12-08 | 2024-06-01 | Boehringer Ingelheim Int | History of imidazopyridine and their use as medicine |
| WO2020087031A1 (en) | 2018-10-26 | 2020-04-30 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| EP4074317A1 (en) | 2021-04-14 | 2022-10-19 | Bayer AG | Phosphorus derivatives as novel sos1 inhibitors |
| CN117185897A (zh) * | 2023-08-31 | 2023-12-08 | 上海泰坦科技股份有限公司 | 一种二氟甲基卤苯的合成方法 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1198739A (zh) | 1995-08-11 | 1998-11-11 | 美国辉瑞有限公司 | (1s,2s)－1－(4－羟基苯基)－2－(4－羟基－4－苯基哌啶－1－基)－1－丙醇甲磺酸盐三水合物 |
| US6476041B1 (en) | 1999-10-29 | 2002-11-05 | Merck & Co., Inc. | 1,4 substituted piperidinyl NMDA/NR2B antagonists |
| HU227197B1 (en) | 2000-10-24 | 2010-10-28 | Richter Gedeon Nyrt | Nmda receptor antagonist carboxylic acid amide derivatives and pharmaceutical compositions containing them |
| ATE324371T1 (de) * | 2001-02-23 | 2006-05-15 | Merck & Co Inc | N-substituierte heterocyclische nichtaryl- nmda/nr2b-antagonisten |
| US7592360B2 (en) | 2003-06-04 | 2009-09-22 | Merck & Co., Inc. | 3-fluoro-piperidines as NMDA/NR2B antagonists |
| SI1648882T1 (sl) | 2003-06-04 | 2009-02-28 | Merck & Co Inc | 3-fluoro-piperidini kot nmda/nr2b antagonisti |
| ES2279446T3 (es) * | 2003-08-15 | 2007-08-16 | MERCK & CO., INC. | Antagonistas nmda/nr2b de 4-cicloalquilaminopirazolo pirimidina. |
| WO2005102390A2 (en) | 2004-04-22 | 2005-11-03 | Pfizer Japan, Inc. | Combinations comprising alpha-2-delta ligands and nmda receptor antagonists |
| WO2006017409A2 (en) | 2004-08-03 | 2006-02-16 | Merck & Co., Inc. | 1,3-disubstituted heteroaryl nmda/nr2b antagonists |
| US20080086006A1 (en) | 2004-12-22 | 2008-04-10 | Nelson Todd D | Process for Making Substituted Piperidines |
| CA2603876A1 (en) * | 2005-04-19 | 2006-10-26 | Merck & Co., Inc. | N-alkyl-azacycloalkyl nmda/nr2b antagonists |
| PT1913000E (pt) | 2005-07-29 | 2012-02-28 | Pfizer Prod Inc | Derivados de pirrolo[2,3-d]pirimidina, suas substâncias intermédias e processo de síntese |
| WO2007061868A2 (en) | 2005-11-17 | 2007-05-31 | Trustees Of Tufts College | Treatment of stereotypic, self-injurious and compulsive behaviors using specific serotonin reuptake inhibitors and antagonists of nmda receptors |
| WO2007099828A1 (ja) | 2006-02-23 | 2007-09-07 | Shionogi & Co., Ltd. | 環式基で置換された含窒素複素環誘導体 |
| EP2114920A1 (en) | 2006-12-27 | 2009-11-11 | Sanofi-Aventis | Substituted isoquinoline and isoquinolinone derivatives |
| WO2010015637A1 (en) | 2008-08-06 | 2010-02-11 | Novartis Ag | New antiviral modified nucleosides |
| WO2011090666A2 (en) | 2009-12-28 | 2011-07-28 | Afraxis, Inc. | Methods for treating autism |
| NZ602777A (en) | 2010-04-16 | 2014-07-25 | Ac Immune Sa | Novel compounds for the treatment of diseases associated with amyloid or amyloid-like proteins |
| WO2011156640A2 (en) | 2010-06-09 | 2011-12-15 | Afraxis, Inc. | 8-(HETEROARYLMETHYL)PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS |
| WO2011159945A2 (en) | 2010-06-16 | 2011-12-22 | Afraxis, Inc. | Methods for treating neurological conditions |
| US9737531B2 (en) | 2012-07-12 | 2017-08-22 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
| WO2012123312A1 (en) | 2011-03-11 | 2012-09-20 | Glaxo Group Limited | Pyrido[3,4-b]pyrazine derivatives as syk inhibitors |
| DK2713722T3 (en) | 2011-05-31 | 2017-07-03 | Celgene Int Ii Sarl | Newly known GLP-1 receptor stabilizers and modulators |
| CA2869216A1 (en) | 2012-04-20 | 2013-10-24 | Ucb Pharma S.A. | Methods for treating parkinson's disease |
| US9708335B2 (en) | 2013-01-29 | 2017-07-18 | Apytinyx Inc. | Spiro-lactam NMDA receptor modulators and uses thereof |
| BR112016025910A8 (pt) | 2014-05-06 | 2021-07-13 | Univ Northwestern | uso de uma quantidade eficaz de glyx-13, uso de glyx-13 e um antagonista de nmdar e composição farmaceuticamente aceitável compreendendo os mesmos |
| EP3152213B1 (en) | 2014-06-04 | 2018-10-31 | Rugen Holdings (Cayman) Limited | Difluoroethylpyridine derivatives as nr2b nmda receptor antagonists |
| DK3194403T3 (en) | 2014-09-15 | 2019-04-15 | Rugen Holdings Cayman Ltd | PYRROLOPYRIMIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS |
| US20180271869A1 (en) | 2014-09-22 | 2018-09-27 | Jie Liu | Treatment of anxiety disorders and autism spectrum disorders |
| WO2016100349A2 (en) | 2014-12-16 | 2016-06-23 | Rugen Holdings (Cayman) Limited | Bicyclic azaheterocyclic compounds as nr2b nmda receptor antagonists |
| US10221182B2 (en) | 2015-02-04 | 2019-03-05 | Rugen Holdings (Cayman) Limited | 3,3-difluoro-piperidine derivatives as NR2B NMDA receptor antagonists |
| WO2016196513A1 (en) | 2015-06-01 | 2016-12-08 | Rugen Holdings (Cayman) Limited | 3,3-difluoropiperidine carbamate heterocyclic compounds as nr2b nmda receptor antagonists |
| US11000526B2 (en) | 2016-11-22 | 2021-05-11 | Rugen Holdings (Cayman) Limited | Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders |
-
2015
- 2015-09-15 DK DK15779059.3T patent/DK3194403T3/en active
- 2015-09-15 WO PCT/US2015/050267 patent/WO2016044323A1/en not_active Ceased
- 2015-09-15 ES ES15779059T patent/ES2723436T3/es active Active
- 2015-09-15 EP EP15779059.3A patent/EP3194403B1/en active Active
- 2015-09-15 SG SG11201701853YA patent/SG11201701853YA/en unknown
- 2015-09-15 CA CA2957898A patent/CA2957898C/en active Active
- 2015-09-15 JP JP2017514306A patent/JP6612331B2/ja active Active
- 2015-09-15 US US14/855,010 patent/US9567341B2/en active Active
- 2015-09-15 RU RU2017107558A patent/RU2017107558A/ru not_active Application Discontinuation
- 2015-09-15 KR KR1020177010056A patent/KR102569031B1/ko active Active
- 2015-09-15 MX MX2017002775A patent/MX2017002775A/es unknown
- 2015-09-15 AU AU2015317886A patent/AU2015317886A1/en not_active Abandoned
- 2015-09-15 CN CN201580049617.5A patent/CN106715435B/zh active Active
-
2017
- 2017-02-09 US US15/428,321 patent/US9968610B2/en active Active
- 2017-02-13 ZA ZA2017/01069A patent/ZA201701069B/en unknown
- 2017-03-08 IL IL251027A patent/IL251027A0/en unknown
-
2018
- 2018-04-24 US US15/961,553 patent/US10420768B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US9567341B2 (en) | 2017-02-14 |
| US9968610B2 (en) | 2018-05-15 |
| EP3194403A1 (en) | 2017-07-26 |
| US20160075713A1 (en) | 2016-03-17 |
| AU2015317886A1 (en) | 2017-03-09 |
| US20170209449A1 (en) | 2017-07-27 |
| KR20170049602A (ko) | 2017-05-10 |
| CN106715435A (zh) | 2017-05-24 |
| EP3194403B1 (en) | 2019-02-06 |
| KR102569031B1 (ko) | 2023-08-22 |
| US10420768B2 (en) | 2019-09-24 |
| CA2957898C (en) | 2023-02-21 |
| WO2016044323A1 (en) | 2016-03-24 |
| RU2017107558A3 (enExample) | 2019-03-18 |
| US20180303834A1 (en) | 2018-10-25 |
| JP2017526724A (ja) | 2017-09-14 |
| JP6612331B2 (ja) | 2019-11-27 |
| DK3194403T3 (en) | 2019-04-15 |
| SG11201701853YA (en) | 2017-04-27 |
| CN106715435B (zh) | 2019-10-01 |
| ZA201701069B (en) | 2019-07-31 |
| ES2723436T3 (es) | 2019-08-27 |
| MX2017002775A (es) | 2017-08-10 |
| RU2017107558A (ru) | 2018-10-18 |
| BR112017004868A2 (pt) | 2017-12-12 |
| CA2957898A1 (en) | 2016-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL252257A0 (en) | Insulin receptor partial agonists | |
| GB201514875D0 (en) | Receptor | |
| GB2545368B (en) | Diversion-resistant opioid formulations | |
| GB201518816D0 (en) | Receptor | |
| IL251027A0 (en) | History of pyrrolopyrimidines as nr2b nmda receptor antagonists | |
| EP3137074A4 (en) | Prostaglandin receptor ep2 antagonists, derivatives, compositions, and uses related thereto | |
| GB2531940B (en) | Process for preparing methotrexate formulation | |
| SG11201605618WA (en) | Selective nr2b antagonists | |
| IL256496B (en) | 5–ht2 blockers | |
| EP3193852A4 (en) | Nmda receptor antagonists for treating gaucher disease | |
| EP3253761A4 (en) | 3,3-difluoro-piperidine derivatives as nr2b nmda receptor antagonists | |
| ZA201605243B (en) | Ethynyl derivatives | |
| EP3154956A4 (en) | Glucagon antagonists | |
| EP3136858A4 (en) | Guanosine as an immunepotentiator mediated through toll receptors | |
| EP3142666A4 (en) | 5-ht4 receptor agonist for gastroparesis | |
| TWM490258U (en) | Folding structure for furniture | |
| ZA201605808B (en) | Process for preparing an endothelin receptor antagonist | |
| HK1231053A1 (en) | Glucagon antagonists | |
| HK1225025A1 (en) | Selective nr2b antagonists | |
| EP3162366A4 (en) | Sweetness receptor antagonist | |
| HK1236210A1 (en) | Insulin receptor partial agonists | |
| TWM489280U (en) | Vibrator table structure | |
| GB201411741D0 (en) | Mixing bowl stand |